Therapeutic | Anifrolumab |
Target | IFNAR1 |
Heavy Chain | EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS |
Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK |
100% seqID Fv Structure | 4qxg [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4qxg [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | Medarex, Medical University of Vienna, MedImmune |
Conditions Approved | na |
Conditions Active | Systemic lupus erythematosus, Lupus nephritis, Rheumatoid arthritis |
Conditions Discontinued | Scleroderma |
Notes |